Glenn Larkin is an IT professional, editor, and photographer, currently writing for Yahoo Finance and Investor's Business Daily. His articles primarily focus on stock market analysis, ratings, and trends, providing insights for investors. Glenn's expertise in the financial sector allows him to deliver informative and timely articles to his readers.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Glenn Larkin's articles primarily focus on investment analysis, stock ratings, and technical analysis within the stock market. His coverage heavily cites data to support his analyses.
Given this focus, Glenn is likely to be interested in pitches that provide unique insights into companies' performance indicators or market trends. If you have proprietary data or expert knowledge in investment analysis, stock evaluations, or technical indicators within the stock market, it could be valuable for pitching ideas to him.
While no specific geographic focus is mentioned for Glenn's coverage area, his topics are universally applicable across financial markets and would not be limited by regional constraints.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Abbott Laboratories shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Star Bulk Carriers shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.
By: Glenn Larkin
On Friday, Arm Holdings ARM ) earned a positive adjustment to its Relative Strength (RS) Rating , from 90 to 98. Thanks to the huge move up after earnings the RS rating also soared.
By: Glenn Larkin
On Tuesday, CRISPR Therapeutics CRSP ) got a positive adjustment to its Relative Strength (RS) Rating , from 89 to 93.
When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is AbbVie, which had its Relative Strength (RS) Rating upgraded from 80 to 84 Wednesday. While this is a positive move, note that the RS Line, which is a different measurement, is not really trending higher.
By: Glenn Larkin
A Relative Strength Rating upgrade for MPLX shows improving technical performance. Will it continue?
By: Glenn Larkin
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.
The IBD SmartSelect Composite Rating for Nutanix rose from 94 to 96 Friday. Nutanix is now out of buy range after clearing the 33.73 entry in a consolidation several months ago. The stock has an 81 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 81% of all stocks.
By: Glenn Larkin
GE HealthCare Techs GEHC ) had its Relative Strength (RS) Rating upgraded from 80 to 83 Monday.
By: Glenn Larkin
A Relative Strength Rating upgrade for Akamai Technologies shows improving technical performance. Will it continue?
(833) 317-6278 
